Healthcare [ 7/13 ] | Biotechnology [ 61/159 ]
NASDAQ | Common Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 7, 24 | 0 Increased by +100% | -0.79 Increased by +100% |
| Mar 26, 24 | 0 Increased by +100% | -0.72 Increased by +100% |
| Nov 9, 23 | -0.66 Decreased by -29.41% | -0.71 Increased by +7.04% |
| Aug 11, 23 | -0.63 | -0.65 Increased by +3.08% |
| May 9, 23 | -0.58 | -0.6 Increased by +3.33% |
| Mar 28, 23 | -0.8 | -1.09 Increased by +26.61% |
| Nov 14, 22 | -0.51 | - |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 0 Decreased by N/A% | -14.47 M Decreased by -64% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0 Decreased by N/A% | -13.91 M Decreased by -143.46% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0 Decreased by N/A% | -11.12 M Decreased by -53.83% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0 Decreased by N/A% | -7.91 M Decreased by -79.19% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 22 | 0 Decreased by N/A% | -8.82 M Decreased by -299.32% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 22 | 0 Decreased by N/A% | -5.71 M Decreased by N/A% | Decreased by N/A% - |
| Mar 31, 22 | 0 Decreased by N/A% | -7.23 M Decreased by N/A% | Decreased by N/A% - |
| Dec 31, 21 | 0 - | -4.42 M - | Decreased by N/A% - |
Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in Phase II clinical trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response, or DDR, pathways; and ACR-2316, a dual WEE1/PKMYT1 inhibitor. Acrivon Therapeutics, Inc. was incorporated in 2018 and is based in Watertown, Massachusetts.